MedTrace Logo

Study to Evaluate CCS1477 in Advanced Tumours

NCT03568656 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-08-08

No results posted yet for this study

Summary

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.

Conditions

Interventions

DRUG

CCS1477

Capsules, oral

DRUG

Abiraterone acetate

Abiraterone acetate 500mg tablets plus prednisone/prednisolone

DRUG

Enzalutamide

Enzalutamide 40mg capsules/tablets

DRUG

Darolutamide

300mg tablets

DRUG

Olaparib

150mg tablets

DRUG

Atezolizumab

840mg/14ml concentrate for solution for infusion vials

Sponsors & Collaborators

  • CellCentric Ltd.

    lead INDUSTRY

Principal Investigators

  • Johann de Bono, MD · Royal Marsden NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-23
Primary Completion
2025-07-06
Completion
2025-07-06
FDA Drug
Yes

Countries

  • United States
  • France
  • Netherlands
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03568656 on ClinicalTrials.gov